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ABSTRACT The persistent nature of chronic wounds leaves them highly susceptible
to invasion by a variety of pathogens that have the ability to construct an extracel-
lular polymeric substance (EPS). This EPS makes the bacterial population, or biofilm,
up to 1,000-fold more antibiotic tolerant than planktonic cells and makes wound
healing extremely difficult. Thus, compounds which have the ability to degrade bio-
films, but not host tissue components, are highly sought after for clinical applica-
tions. In this study, we examined the efficacy of two glycoside hydrolases, -amylase
and cellulase, which break down complex polysaccharides, to effectively disrupt
Staphylococcus aureus and Pseudomonas aeruginosa monoculture and coculture bio-
films. We hypothesized that glycoside hydrolase therapy would significantly reduce
EPS biomass and convert bacteria to their planktonic state, leaving them more sus-
ceptible to conventional antimicrobials. Treatment of S. aureus and P. aeruginosa
biofilms, grown in vitro and in vivo, with solutions of -amylase and cellulase re-
sulted in significant reductions in biomass, dissolution of the biofilm, and an in-
crease in the effectiveness of subsequent antibiotic treatments. These data suggest
that glycoside hydrolase therapy represents a potential safe, effective, and new ave-
nue of treatment for biofilm-related infections.
KEYWORDS Pseudomonas aeruginosa, Staphylococcus aureus, biofilms, chronic
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Chronic wound bacterial biofilm infections (CWIs), which include pressure, diabetic,venous, and arterial ulcers, are a major clinical and economic burden worldwide. In
fact, chronically infected diabetic foot ulcers are considered the most significant wound
care problem in the world (1). Between 5 and 7 million Americans are treated for
chronic wounds annually, at an estimated cost of 10 to 20 billion dollars per year, an
expense which is expected to increase as the prevalence of risk factors, such as obesity
and diabetes, grows (2). CWIs largely owe their chronicity to the inability of the host to
clear a biofilm, with or without clinical intervention. Biofilms are communities of
microorganisms protected by a self-synthesized layer of complex polymers represented
mainly by polysaccharides, proteins, and extracellular DNA (eDNA), also called the
extracellular polymeric substance (EPS). Biofilms form when a primary, planktonic
bacterium irreversibly attaches itself to a surface and commences rapid division and
recruitment of other microorganisms by providing more diverse adhesion sites to the
substrate (3). Under the protection of the EPS, such polymicrobial infections thrive,
making wound healing difficult.
Several mechanisms have been proposed to explain how biofilms can contribute to
the chronicity of wounds, including acting as a mechanical barrier against both
host-derived and exogenous antimicrobial agents, as well as impeding the reepitheli-
alization process. This leads to a perpetual state of inflammation that delays wound
healing (4, 5). It is estimated that more than 90% of all chronic wounds contain bacteria
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that are biofilm associated (6), making them up to 1,000-fold more tolerant to antibi-
otics and the host immune response (7). Thus, taking into account the alarming
increase of antibiotic-resistant bacteria, the added ability of pathogens to reside within
the protection of the biofilm matrix all too often makes effective treatment of these
infections impossible.
In the majority of biofilms, microorganisms make up less than 10% of the dry mass,
while the EPS represents more than 90%, with polysaccharides often being a major
constituent (8). These polysaccharides provide a variety of functions crucial to the
formation and integrity of the biofilm, including, but not limited to, initial surface
adhesion, aggregation of bacterial cells, water retention, mechanical stability, sorption
of nutrients and ions, nutrient storage, and binding of enzymes, and serve as a
protective barrier against antimicrobial agents and environmental stressors (8). Thus,
active degradation of polysaccharides may prove to be a promising, universally appli-
cable approach to clinically addressing biofilm infections. Glycoside hydrolases (GHs)
are enzymes that act by hydrolyzing the glycosidic linkages between two or more
carbohydrates (9). They can be individually characterized by the specific type of linkage
that they cleave, such as -1,4 bond hydrolysis by -amylase, -1,4 bond hydrolysis by
cellulase, or -1,3 bond hydrolysis by -1,3 galactosidase (Fig. 1) (10, 11). Considering
the important contribution of polysaccharides to the biofilm architecture, it has been
hypothesized that hydrolyzing the glycosidic linkages that hold them together will lead
to degradation of the EPS. Indeed, microorganisms themselves utilize specific glycoside
hydrolases to initiate dispersal events. For example, dispersin B is a -hexosaminidase
produced by the Gram-negative bacterium Aggregatibacter actinomycetemcomitans in
order to disperse adherent cells from a mature biofilm (12). It has been shown that
exogenous addition of dispersin B is capable of preventing and disrupting biofilms in
vitro and in vivo (13–17).
The polysaccharide composition of multiple, biofilm-producing bacterial pathogens
has been elucidated (18–20). One glycosidic linkage commonly seen within the exopo-
lysaccharides secreted by a wide range of pathogens is the -1,4 bond, such as that
present in cellulose, an exopolysaccharide produced by many strains of Escherichia coli,
Salmonella, Citrobacter, Enterobacter, Pseudomonas, and other bacteria (21). Cellulase is
a commercially available enzyme that hydrolyzes these -1,4 linkages (22) and thus
could theoretically serve to break up a host of biofilm exopolysaccharides into simple
sugars. It has been shown that cellulase inhibits biofilm growth by Burkholderia cepacia
and Pseudomonas aeruginosa on various abiotic surfaces commonly used in medical
devices (22, 23). Similarly, -amylase, a GH that acts by cleaving the -1,4 straight-chain
linkage, has been previously shown to both inhibit biofilm formation and disrupt
preformed biofilms of Vibrio cholerae, Staphylococcus aureus and P. aeruginosa in vitro
(24–26). In this study, we aimed to hydrolyze the polysaccharides produced by S. aureus
and P. aeruginosa in dual-species polymicrobial biofilms by targeting a pair of highly
conserved glycosidic linkages. We focused on S. aureus and P. aeruginosa because they
are the two most commonly isolated bacterial species in CWIs and are often found
together in polymicrobial infections (27, 28). We found that -amylase and cellulase
were able to disrupt S. aureus and P. aeruginosa biofilms, leading to increased dispersal
and antibiotic efficacy.
FIG 1 Examples of various glycosidic linkages found within the exopolysaccharides of biofilm EPS and
the enzymes that hydrolyze them.
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RESULTS
Glycoside hydrolase treatment reduces biofilm biomass and increases bacterial
dispersal. We first tested the ability of -amylase and cellulase to disrupt S. aureus and
P. aeruginosa biofilms that were grown on plastic cell culture coverslips. After 48 of
bacterial growth, the biofilm-coated coverslips were treated with a 0.25% GH solution
for 30 min, and the biomass of the biofilms was estimated by the retention of crystal
violet (CV) stain (Fig. 2). A significant reduction in biomass was observed after treatment
with both GHs but not with a GH that had been heat inactivated. Significant degrada-
tion was seen at concentrations as low as 0.0025% and at treatment times as short as
2 min (see Fig. S1 in the supplemental material).
Given the degradation of biofilm biomass, we expected the biofilm-associated cells
to be dispersed into their planktonic state due to the loss of EPS structure. We
performed an in vitro well plate dispersal assay to measure total cell dispersal. S. aureus
and P. aeruginosa coculture biofilms, grown in the wells of a non-tissue culture-treated
plate, were treated with 5% GH solutions, and the percentage of total cells that were
dispersed into the supernatant was calculated. -Amylase, cellulase, and a 1:1 solution
of both all resulted in a significant amount of dispersal compared to results with vehicle
and heat-inactivated controls (Fig. 3). Solutions at concentrations of 0.25%, like those
utilized in the crystal violet assays, also resulted in significant, albeit less, dispersal (Fig.
S2). While the bacterial population started off with roughly equal numbers of P.
aeruginosa and S. aureus bacteria, by 24 h P. aeruginosa represented most of the
population. This is likely due to the production of several virulence factors by P.
aeruginosa which are lethal to S. aureus (30). However, as we have seen before (31),
when the two were cultured in vivo and under wound-like, in vitro conditions, the CFU
counts for the two bacterial species were roughly equal. It should also be noted that the
overall number of CFU present (in supernatant plus biofilm) in all treatment groups did
not differ significantly (Fig. S3). Only the percentage of total cells present in the
supernatant after GH treatment was significantly shifted, indicating that GHs do not
appear to have any bactericidal activity but simply break down biofilm.
In order to determine if the results obtained in vitro translated to a more clinically
relevant model, we next tested the ability of GH solutions to degrade the biomass of,
and disperse the cells from, biofilms grown in vivo. A murine chronic wound infection
model was utilized, and wounds were coinfected with S. aureus and P. aeruginosa.
Briefly, after anesthesia, 1.5-cm by 1.5-cm full-thickness wounds were administered on
FIG 2 GHs reduce the biomass of polymicrobial biofilms. Traditional crystal violet biofilm assays (29) were
performed after 48 h of coculturing S. aureus and P. aeruginosa. Planktonic cells were removed, and
biofilms were treated with 0.25% GH solutions (-amylase, cellulase, or -amylase plus cellulase
[AmCell]), vehicle, or heat-inactivated (HI) controls for 30 min before they were stained with 1% crystal
violet. One-way analysis of variance and a Tukey-Kramer multiple-comparison test were used to test for
differences between results. **, P  0.01; ***, P  0.001.
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the dorsal surface of mice and covered with a transparent, adhesive bandage under
which the bacteria were injected. At 3 days postinfection, we extracted the biofilms
from the wound beds and treated them with GHs. For analysis of biomass degradation,
we measured the weights of the extracted wound beds before and after treatment with
GHs and compared the percent reduction in weight to that of biofilms treated with
heat-inactivated GH. We found that -amylase and cellulase, both alone and in a 1:1
mixture, were able to degrade S. aureus and P. aeruginosa polymicrobial biofilms
harvested from murine chronic wounds (Fig. 4A). It should be noted that biomass loss
in the heat-inactivated control is likely due to osmosis-powered diffusion into the
distilled water over the 1 h of treatment time. To test whether GHs had any degradative
effects on tissue alone, we performed the same GH treatment on uninfected connective
tissue extracted from the wound beds of mice and saw no reduction in the tissue
weight due to treatment (Fig. 4A). This indicates that GH treatment causes the disso-
FIG 3 GHs disperse bacterial cells in vitro. S. aureus and P. aeruginosa biofilms at 48 h were treated with
5% GH solutions (-amylase, cellulase, or amylase plus cellulase [AmCell]), vehicle, or heat-inactivated
controls (HI) for 30 min. Percent dispersal was calculated as follows: (number of CFU in the supernatant)/
(number of CFU in the supernatant  number of CFU remaining in the biofilm). One-way analysis of
variance and a Tukey-Kramer multiple-comparison test were used to test for differences between results.
Note that the result for amylase plus cellulase were not significantly greater than the result for either
-amylase or cellulase alone. ***, P  0.001.
FIG 4 GHs degrade and disperse bacterial cells ex vivo. Tissue was extracted from the wounds of mice coinfected with S. aureus and P. aeruginosa and treated
with -amylase, cellulase, or both (AmCell) and compared to treatment with heat-inactivated (HI) and/or uninfected controls. Extracted tissue was suspended
in 5% enzyme solutions for 1 h. (A) Percent biomass degraded was calculated as follows: (posttreatment weight/pretreatment weight). (B) Percent dispersal was
calculated as follows: (number of CFU in the supernatant)/(number of CFU in supernatant  number of CFU remaining wound tissue associated). One-way
analysis of variance and a Tukey-Kramer multiple-comparison test were used to test for differences between results. **, P  0.01; ***, P  0.001.
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lution of up to half of the weight of the material present in the wound beds of infected
(but not uninfected) mice. To determine whether this reduction in biomass correlated
with bacterial cell dispersal, we also calculated the numbers of viable bacteria that were
located in the treatment solution versus the number in the remaining biofilm after
treatment with active or heat-inactivated GH. We found that -amylase, cellulase, and
a 1:1 solution of -amylase and cellulase resulted in significantly more total cell
dispersal than treatment with vehicle and heat-inactivated controls (Fig. 4B). Cell
dispersal into the control solutions was likely due to osmosis over the 1-h treatment
time, as mentioned above for biomass degradation.
Taken together, these results indicate that hydrolysis of glycosidic linkages of EPS
exopolysaccharides by -amylase and cellulase leads to degradation of mature biofilms
grown in vitro and in vivo and that this degradation leads to the dispersal, or planktonic
release, of biofilm-resident bacterial cells.
Glycoside hydrolase therapy increases antibiotic efficacy. Bacterial cells residing
within the protection of a biofilm are thought to exhibit greater tolerance to antibiotics
due to the inability of certain drugs to penetrate the EPS and to the sessile, dormant
nature that many biofilm-dwelling bacteria adopt (32). Thus, we would expect dis-
persed, planktonic cells resulting from GH treatment to be more susceptible to anti-
biotics. To begin testing this, we utilized the Lubbock wound model (LWM), a clinically
relevant in vitro wound-like model (31, 33, 34), in which we inoculated S. aureus and P.
aeruginosa. After 48 h of growth, the resulting biofilms were extracted and treated
either with antibiotic alone or with antibiotic plus GH; the posttreatment CFU were
enumerated, and counts were compared to those of the heat-inactivated control. We
found that a 1:1 mixture of -amylase and cellulase increased the efficacy of gentamicin
sulfate against biofilm-resident bacteria compared to treatment with gentamicin sulfate
alone (Fig. 5). Gentamicin sulfate was used because it is a positively charged aminogly-
coside, and it has been shown that positively charged antibiotics are less able to
penetrate the largely negatively charged biofilm EPS (35). This makes aminoglycosides
ideal for studying changes in antibiotic efficacy due to EPS destruction. We have
previously seen that approximately half of P. aeruginosa and S. aureus cells remain
viable after gentamicin treatment when they are cocultured in the LWM (31), and that
finding was consistent in these experiments. However, we also found that GH pretreat-
ment significantly increased the efficacy of gentamicin (Fig. 6). Taken together, these
data suggest that degradation of EPS polysaccharides with GH significantly increases
the ability of antibiotics to act upon the resident bacteria by dispersing the cells from
the protection of the biofilm.
DISCUSSION
The ability of pathogens to exist within the protection of a biofilm poses wide-
reaching complications to our ability to successfully clear infections. In particular, CWIs,
FIG 5 GHs degrade biofilms and improve the efficacy of antibiotics in vitro. (A) One hour of treatment with 10%
cellulase (shown) and -amylase completely disassociates 24-h-old polymicrobial biofilms (S. aureus plus P.
aeruginosa) cultured in wound-like medium. (B) Treatment of wound-like biofilms with 5% -amylase plus 5%
cellulase plus 200 g/ml gentamicin sulfate was more effective at killing S. aureus (SA) and P. aeruginosa (PA) than
treatment with gentamicin alone. One-way analysis of variance and a Tukey-Kramer multiple-comparison test were
used to test for differences between results. **, P  0.01; ***, P  0.001.
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such as diabetic foot ulcers, are significantly more recalcitrant and recurrent when
harboring a biofilm infection (6, 36–38). As exopolysaccharides represent a substantial
and important constituent of many bacterial biofilms and contribute to both the
physical and chemical stability of the EPS (8), their degradation should disperse bacteria
into their planktonic state and may afford the host improved healing abilities by
increasing the access of the host immune system and of administered antimicrobials/
antibiotics to the cells.
Several studies have shown the ability of exogenous GHs to inhibit biofilm formation
and disrupt mature biofilms. Recently, Baker et al. showed that GHs specific for the
polysaccharides Pel and Psl are capable of both preventing the formation of and
degrading P. aeruginosa biofilms in vitro, as well as potentiating antibiotics and
increasing the ability of neutrophils to kill the bacteria (39). However, to our knowledge
GHs have not until now been tested against biofilms grown in vivo. Ideally, GHs to be
used clinically would exhibit broad efficacy against a variety of polysaccharides pro-
duced by vastly different species of pathogens, especially considering the complex
polymicrobial nature of most infections (40). Therefore, it stands to reason that GHs that
target highly conserved glycosidic linkages would be highly advantageous. In this way,
clinicians would be able to administer the enzymes to any patient presenting with a
biofilm infection, regardless of the causative microorganisms, and have a reasonable
expectation that the therapy will be effective. -Amylase and cellulase are two inex-
pensive, commercially available GHs that target common linkages found in the EPS
made by many different species of bacteria, and multiple studies have shown that they
can inhibit and disrupt the preformed in vitro biofilms of a variety of bacterial species
(22–26).
In this study, we investigated the clinical applicability of utilizing -amylase and/or
cellulase to disrupt CWIs by utilizing the biologically relevant LWM, as well as a CV
biomass assay, an in vitro cell dispersal assay, and an established murine chronic wound
infection model. We found that -amylase and cellulase, separately and in combination,
significantly degraded established, polymicrobial biofilms formed in vitro, resulting in
dispersal of the biofilm-resident bacteria into the supernatant. It is known that plank-
tonic cells are more susceptible than their biofilm-resident counterparts to killing by
both the immune system and antimicrobials/antibiotics (41–43) due, in part, to the
higher metabolic rates and better cell surface access to free-floating cells. Antibiotic
treatment of polymicrobial biofilms grown in the LWM and in our murine chronic
wound model displayed increased efficacy when combined with GH, suggesting that
targeting highly conserved glycosidic linkages with GHs may improve the ability of
both the host and the clinician to eradicate recalcitrant biofilm infections.
Future work will be focused on optimizing the biodelivery of GHs, with and without
FIG 6 GHs improve the efficacy of antibiotics ex vivo. Treatment of murine chronic wound biofilms with
5% -amylase plus 5% cellulase plus 200 g/ml gentamicin sulfate was more effective at killing S. aureus
(SA) and P. aeruginosa (PA) than treatment with gentamicin alone. One-way analysis of variance and a
Tukey-Kramer multiple-comparison test were used to test for differences between results. *, P  0.05; **,
P  0.01.
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antibiotics, in animal wound infection models in situ. Before clinical applications can be
explored, several questions must be addressed, such as the following: What is the most
efficacious vehicle for topical administration (e.g., hydrogel or irrigation solution with or
without negative pressure)? What species of bacteria and/or fungi can be successfully
targeted? Can GHs be used alone to potentiate clearing of the infection by the immune
system? Do GHs increase the efficacy of all antibiotics or just certain classes? What is the
effect on the host when such a massive dispersal event is triggered? Also, given that
there is a range of metabolic activities within the biofilm-associated bacterial cell
population, from fully metabolically active to nearly dormant (i.e., persister cells) (44)
cells, and that the majority of antibiotics target metabolically active, replicating cells,
what happens to these dormant cells once they are dispersed from the biofilm? It is
possible that freeing these cells from the protection of the biofilm will render them
more visible to opsonic and nonopsonic phagocytosis and that metabolic activity will
resume, making the cells more susceptible to antibiotics. Thus, while many questions
need to be answered before GHs can be used clinically, they appear to be a very
promising method of dispersing biofilm and making highly refractory infections sus-
ceptible to conventional treatments.
MATERIALS AND METHODS
Bacterial strains. P. aeruginosa strain PAO1 (45) and S. aureus strain SA31 (46) have been previously
described. S. aureus and P. aeruginosa were grown in baffled Erlenmeyer flasks, with shaking at 200 rpm,
in Luria-Bertani (LB) broth at 37°C. Planktonically grown cells were then used to initiate infection in the
in vitro and in vivo models. All CFU were quantified by serial dilution and 10-l spot plating on
Staphylococcus medium 110 (Difco) and Pseudomonas isolation agar (Difco).
Glycoside hydrolases. Bacterial -amylase (from Bacillus subtilis) (02100447; MP Biomedicals, LLC)
and fungal cellulase (from Aspergillus niger) (02150583; MP Biomedicals, LLC) were utilized for these
experiments. All enzymes were prepared by dissolving lyophilized powder in either double-distilled
water (ddH2O) or 1 phosphate-buffered saline (PBS) at 65°C for 5 min. Heat-inactivated controls were
generated by heating the enzyme solutions at 95°C for 20 min.
CV assay. A traditional in vitro crystal violet (CV) biomass assay (29) was performed by inoculating
the wells of a 24-well non-tissue culture-treated plate (Falcon) containing 13-mm plastic cell culture
coverslips with 1:100 dilutions of overnight cultures of S. aureus and P. aeruginosa in fresh LB broth and
allowing 48 h of growth at 37°C, with shaking at 80 rpm. Planktonic cells were then removed via rinsing
with PBS, and the biofilm-coated coverslips were treated with enzyme solutions, vehicle, or heat-
inactivated controls. After treatment, the coverslips were rinsed with ddH2O, and the remaining biomass
was stained with 1% CV in ddH2O for 20 min. Coverslips were then rinsed once more with ddH2O and
transferred to fresh wells in which the CV was eluted in 95% ethanol for 1 h. The eluted CV from treated
versus untreated samples was quantified via absorbance of 595-nm light in a Synergy H1 Hybrid Reader
(Biotek).
In vitro cell dispersal. To measure percent dispersal in vitro, the wells of a 24-well non-tissue
culture-treated plate (Falcon) were inoculated with 1:100 dilutions of overnight cultures of S. aureus and
P. aeruginosa, and biofilms were allowed to grow for 48 h at 37°C, with shaking at 80 rpm. Following
incubation, the supernatant was removed, and each well was gently rinsed with PBS to discard any
nonattached biomass. Subsequently, wells were treated with enzyme solutions, vehicle, or heat-
inactivated controls. Following treatment, the supernatant was removed and centrifuged at a relative
centrifugal force (RCF) of 11,000 for 10 min in order to pellet the cells. Cell pellets were then resuspended
in PBS for CFU quantification. Biofilm remaining on the wells was dispersed via sonication and suspended
in PBS for CFU quantification. Percent bacterial cell dispersal was calculated by finding the quotient of
the total CFU (biofilm-associated plus planktonic) count divided by the planktonic CFU (in the superna-
tant) count.
Lubbock chronic wound biofilm model. The Lubbock chronic wound biofilm model, or Lubbock
wound model (LWM), has been previously described (31, 33, 34). Briefly, wound-like medium (50% bovine
plasma, 45% Bolton broth, 5% laked horse blood) was inoculated with 105 bacterial cells and incubated
for 48 h, statically, at 37°C. Following incubation, the resulting biofilms were extracted, weighed, and
treated with a vehicle control (ddH2O), GH, or GH plus antibiotics. Percent bacterial cell dispersal was
calculated by finding the quotient of the total CFU (biofilm-associated plus planktonic) count divided by
the planktonic CFU (in the supernatant) count. Percent biomass degraded was calculated by rinsing
samples to remove the posttreatment supernatant, weighing the remaining biomass, and finding the
quotient of the posttreatment biofilm weight divided by the pretreatment biofilm weight. Percent
antibiotic tolerance was obtained by treating biofilms with GH or with GH plus antibiotic and finding the
quotient of the antibiotic-treated biofilm CFU count/gram divided by the GH-only treated biofilm CFU
count/gram.
Murine chronic wound model. Our murine chronic wound model has been previously described
(34, 36, 47, 48). Briefly, mice were anesthetized by intraperitoneal injection of sodium pentobarbital. After
a surgical plane of anesthesia was reached, the backs were shaved and administered a full-thickness,
dorsal, 1.5- by 1.5-cm excisional skin wound to the level of panniculus muscle with surgical scissors.
Enzymatic Degradation of Chronic Wound Biofilms Antimicrobial Agents and Chemotherapy
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Wounds were then covered with a semipermeable polyurethane dressing (Opsite dressing; Smith and
Nephew), under which 104 bacterial cells were injected into the wound bed. Biofilm formation was
allowed to proceed for 72 h, after which the mice were euthanized, and the wound beds were harvested
for ex vivo treatment with vehicle control, GH alone, or GH plus antibiotic. Percent dispersal, percent
biomass degraded, and antibiotic tolerance were calculated as with the LWM, described above.
All animal experiments were carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved
by the Institutional Animal Care and Use Committee of Texas Tech University Health Sciences Center
(IACUC protocol number 07044).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
AAC.01998-16.
TEXT S1, PDF file, 0.6 MB.
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